ArticleNeuroendocrinology2025
Real-World Patient Outcomes on the Efficacy of Lanreotide Treatment for Neuroendocrine Tumors: The Influence of Body Mass Index, Body Surface Area, and Renal Function.
Article in Neuroendocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Introduction: Lanreotide is an effective and safe first-line therapy to treat patients with a gastroenteropancreatic (GEP) neuroendocrine tumor (NET). Precision oncology may be used to provide each patient with the right dosage. Pharmacokinetic data suggest lower exposure in higher weight patients. However, no recommendations for dose individualization in specific patient groups exist. Therefore, we aimed to investigate the association of body mass index (BMI), body surface area (BSA), and renal function on the efficacy and toxicity of lanreotide treatment for NETs.
methodsGEP-NET patients on lanreotide treatment at Amsterdam UMC from 2016 to 2022 were included. Outcome measures were primarily PFS and secondarily OS and toxicity. Kaplan-Meier analyses and Cox's proportional hazard models were used to calculate median PFS/OS and compare subgroups based on BMI, BSA, and renal function.
resultsA total of 122 patients with NETs of diverse origin, functionality, and grade were included with a median PFS of 28 months (95% CI, 19.3-36.7). The median OS was not reached. No statistically significant difference in PFS among BMI subgroups was observed, although obese patients had the longest PFS (52 months, 95% CI, 27.4-76.7) compared to other BMI categories. No relation between BSA/renal function and PFS or toxicity was found.
conclusionThis large real-world data cohort of NET patients treated with lanreotide found no association of BMI, BSA, or renal function with PFS. Dose individualization of lanreotide treatment based on the patient characteristics BMI, BSA, or renal function does not seem rational based on these findings. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.